La chemioterapia del microcitoma disseminato. Confronto tra carboplatino-etoposide e ciclofosfamide-epirubicina-etoposide

Translated title of the contribution: Chemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide

Davide Tassinari, Giovenzio Genestreti, Enzo Pasquini, Manuela Fantini, Barbara Poggi, Emiliano Tamburini, Maximilian Papi, Giorgio Ioli, Giovanni Oliverio, Francesca Fochessati, Valentina Arcangeli, Vanessa Agostini, Anna Maria Mianulli, Manuela Imola, Pier Paolo Fattori, Alberto Ravaioli

Research output: Contribution to journalArticle

Abstract

Although cisplatin and etoposide seem to represent the treatment of choice in Small-Cell Lung Cancer, a lot of data exist in literature supporting both the use of anthracycline-containing regimens and the use of alternating regimens where platinum-containing regimens and anthracycline-containing regimens are alternatively used as first line in the same patient. In our paper we review the outcomes of two different series of patients treated with ciclophosphamide- epidoxorubicin-etoposide (CEVP16) or carboplatin-etoposide (CBE) for extended Small-Cell Lung Cancer. Sixty-three patients (53.4%) were treated with CEVP16 and 55 patients (46.6%) with CBE. Response Rate (complete plus partial responses) was greater in patients treated with CEVP16 (49.2%) when compared with the response rate in patients treated with CBE (30.9%) (p=0.04 using the Chi-Square test); no differences were observed in the median time to progression (235 vs 199 days, using the Log-Rank test). Overall survival was greater in the CEVP16 group when compared with the CBE one (281 vs 208 days and 35.6% vs 16.3% of patients alive after 2 years of follow up for CEVP16 and CBE respectively, p=0.02 using the Log-Rank test). Although our data present all the methodological limits of the "case-series", it is interesting to observe how an anthracycline-containing regimen seems to be more effective than a platinum-containing one and how it could still play a role in the treatment of extended Small-Cell Lung Cancer.

Translated title of the contributionChemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide
Original languageItalian
Pages (from-to)234-239
Number of pages6
JournalRecenti Progressi in Medicina
Volume96
Issue number5
Publication statusPublished - May 2005

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Chemotherapy in extended small-cell lung cancer. Retrospective analysis of two different series of patients treated with carboplatin and etoposide or ciclophosphamide-epidoxorubicin and etoposide'. Together they form a unique fingerprint.

  • Cite this

    Tassinari, D., Genestreti, G., Pasquini, E., Fantini, M., Poggi, B., Tamburini, E., Papi, M., Ioli, G., Oliverio, G., Fochessati, F., Arcangeli, V., Agostini, V., Mianulli, A. M., Imola, M., Fattori, P. P., & Ravaioli, A. (2005). La chemioterapia del microcitoma disseminato. Confronto tra carboplatino-etoposide e ciclofosfamide-epirubicina-etoposide. Recenti Progressi in Medicina, 96(5), 234-239.